Company / EPS (Basic)
Edgewise Therapeutics, Inc. EPS (Basic) History
FY2020-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Basic)
-$1.63
FY2025
5-year range
-$1.63 / -$1.14
FY2021-FY2025
Trend
-12.4%
vs FY2024
Sector context
#109 of 208
Health Care
What the data says
At $-1.63, Edgewise Therapeutics, Inc.'s eps (basic) ranks #109 of 208 in the Health Care sector. EPS (Basic) has fluctuated over the past 6 years, ranging from $-23.17 in FY2020 to $-1.14 in FY2021.
Based on SEC 10-K filings.
-1.63 in FY2025.
Declined from $-1.57 to $-1.63 over the past 2 years.
Health Care sector context is included.
EPS (Basic) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#109 of 208 in Health CareTop 52% of 208This company -$1.63 Sector average -$0.96
▼
-69.2% below sector average
Key checks
Key Insights
- In FY2025, eps (basic) decreased 12.4% year-over-year.
- Ranks #109 out of 208 companies in the Health Care sector.
- Peak eps (basic) was recorded in FY2021.
- Lowest eps (basic) in the period was in FY2020.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score 6.82 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Basic)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$1.63 | -12.4% |
| FY2024 | -$1.45 | +7.6% |
| FY2023 | -$1.57 | -24.6% |
| FY2022 | -$1.26 | -10.5% |
| FY2021 | -$1.14 | +95.1% |
| FY2020 | -$23.17 | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026